psilocin
Small moleculeexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 26, 2022 (NCT05317689)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Dopamine D2 receptor and Serotonin 2a receptor (D2 and 5HT2a) agonist
Chemistry & pharmacology
Loading structure…
SMILES
CN(C)CCc1c[nH]c2cccc(O)c12- Mol. weight
- 204.27 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL65547 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06035900 | Phase 1 | Jun 21, 2023 | Lobe Sciences Ltd., Pharmaceutical Research Unit, Jordan |
| NCT05434156 | Phase 1/Phase 2 (Phase 2) | Oct 27, 2022 | Eleusis Therapeutics, MAC Clinical Research |
| NCT05317689 | Phase 1 | May 26, 2022 | Filament Health Corp., University of California, San Francisco |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eleusis Therapeutics | For profit | 1 | 1 | 1 | 2022 |
| Filament Health Corp. | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Lobe Sciences Ltd. | For profit | 1 | 1 | 1 | 2023 |
| MAC Clinical Research | For profit | 1 | 0 | 1 | 2022 |
| Pharmaceutical Research Unit, Jordan | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2022 |
6 organizations
Page 1 / 1